Cancer Research Targets Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerber, H.-P.
Right arrow Articles by Ferrara, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerber, H.-P.
Right arrow Articles by Ferrara, N.
[Cancer Research 60, 6253-6258, November 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Complete Inhibition of Rhabdomyosarcoma Xenograft Growth and Neovascularization Requires Blockade of Both Tumor and Host Vascular Endothelial Growth Factor

Hans-Peter Gerber, Joe Kowalski, Daniel Sherman, David A. Eberhard and Napoleone Ferrara1

Departments of Molecular Oncology [H-P. G., J. K., D. S., N. F.] and Pathology [D. A. E.], Genentech Incorporated, South San Francisco, California 94080

Growth of the human rhabdomyosarcoma A673 cell line in nude mice is substantially reduced but not completely suppressed after systemic administration of the antihuman vascular endothelial growth factor (VEGF) monoclonal antibody (Mab) A.4.6.1. Potentially, such escape might be attributable to incomplete local penetration of the antibody because of a diffusion barrier associated with tumor growth. Alternatively, it might reflect a compensatory up-regulation of murine VEGF, produced by the stroma of the host, or of other angiogenic factor genes. To test these potential mechanisms, systemic administration of Mab A.4.6.1. was performed in conjunction with intratumoral administration of an irrelevant antibody, an antihuman VEGF Fab or mFlt(1-3)-IgG that neutralizes both human and murine VEGF. Tumor growth in the systemic-plus-intratumoral anti-VEGF group was not different from that in the systemic anti-VEGF-plus-intratumoral-control antibody group, arguing against the possibility that bioavailability is the factor that limits the antitumor efficacy of Mab A.4.6.1. However, intratumoral mFlt(1-3)-IgG administration dramatically enhanced the activity of systemic anti-VEGF Mab and resulted in complete suppression of tumor growth, which indicated that host VEGF significantly contributes to tumor growth. Systemic administration of mFlt(1-3)-IgG alone replicated these findings. Histological analysis of residual tumor tissues revealed an almost complete absence of host-derived vasculature and massive tumor-cell necrosis in the mFlt(1-3)-IgG groups. Such extensive necrotic areas were not present in the other groups. Real-time reverse transcription-PCR analysis of total RNA derived from tumor tissues indicated strong up-regulation of both human and murine VEGF as well as other genes regulated by hypoxia. Our findings emphasize the need to completely block VEGF for maximal inhibition of tumor growth.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Frentzen, Y. A. Yu, N. Chen, Q. Zhang, S. Weibel, V. Raab, and A. A. Szalay
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy
PNAS, August 4, 2009; 106(31): 12915 - 12920.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. G. Bender, P. C. Adamson, J. M. Reid, L. Xu, S. Baruchel, Y. Shaked, R. S. Kerbel, E. M. Cooney-Qualter, D. Stempak, H. X. Chen, et al.
Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., January 20, 2008; 26(3): 399 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
A. Kadenhe-Chiweshe, J. Papa, K. W. McCrudden, J. Frischer, J.-O Bae, J. Huang, J. Fisher, J. H. Lefkowitch, N. Feirt, J. Rudge, et al.
Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation
Mol. Cancer Res., January 1, 2008; 6(1): 1 - 9.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Korsisaari, J. Ross, X. Wu, M. Kowanetz, N. Pal, L. Hall, J. Eastham-Anderson, W. F. Forrest, N. Van Bruggen, F. V. Peale, et al.
Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1
Clin. Cancer Res., January 1, 2008; 14(1): 249 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. M. L. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
PNAS, October 23, 2007; 104(43): 17069 - 17074.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Korsisaari, I. M. Kasman, W. F. Forrest, N. Pal, W. Bai, G. Fuh, F. V. Peale, R. Smits, and N. Ferrara
From the Cover: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice
PNAS, June 19, 2007; 104(25): 10625 - 10630.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H.-P. Gerber, X. Wu, L. Yu, C. Wiesmann, X. H. Liang, C. V. Lee, G. Fuh, C. Olsson, L. Damico, D. Xie, et al.
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies
PNAS, February 27, 2007; 104(9): 3478 - 3483.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Su, Q. Zheng, M. M. Vaughan, Y. Bu, and I. H. Gelman
SSeCKS Metastasis-Suppressing Activity in MatLyLu Prostate Cancer Cells Correlates with Vascular Endothelial Growth Factor Inhibition
Cancer Res., June 1, 2006; 66(11): 5599 - 5607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L. Tejada, L. Yu, J. Dong, K. Jung, G. Meng, F. V. Peale, G. D. Frantz, L. Hall, X. Liang, H.-P. Gerber, et al.
Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor {alpha} Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma.
Clin. Cancer Res., May 1, 2006; 12(9): 2676 - 2688.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. V. Subramanian, T. M. Bui Nguyen, A. M. Truskinovsky, J. Tolar, B. R. Blazar, and S. Ramakrishnan
Adeno-Associated Virus-Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival.
Cancer Res., April 15, 2006; 66(8): 4319 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Fuh, P. Wu, W.-C. Liang, M. Ultsch, C. V. Lee, B. Moffat, and C. Wiesmann
Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the AvastinTM Fab
J. Biol. Chem., March 10, 2006; 281(10): 6625 - 6631.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. A. Moffat, M. Chen, M. S.T. Kariaapper, D. A. Hamstra, D. E. Hall, J. Stojanovska, T. D. Johnson, M. Blaivas, M. Kumar, T. L. Chenevert, et al.
Inhibition of Vascular Endothelial Growth Factor (VEGF)-A Causes a Paradoxical Increase in Tumor Blood Flow and Up-Regulation of VEGF-D
Clin. Cancer Res., March 1, 2006; 12(5): 1525 - 1532.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. du Manoir, G. Francia, S. Man, M. Mossoba, J. A. Medin, A. Viloria-Petit, D. J. Hicklin, U. Emmenegger, and R. S. Kerbel
Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts
Clin. Cancer Res., February 1, 2006; 12(3): 904 - 916.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Malik, M. E. Baldwin, F. Peale, G. Fuh, W.-C. Liang, H. Lowman, G. Meng, N. Ferrara, and H.-P. Gerber
Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice
Blood, January 15, 2006; 107(2): 550 - 557.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W.-C. Liang, X. Wu, F. V. Peale, C. V. Lee, Y. G. Meng, J. Gutierrez, L. Fu, A. K. Malik, H.-P. Gerber, N. Ferrara, et al.
Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF
J. Biol. Chem., January 13, 2006; 281(2): 951 - 961.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Jubb, H. I. Hurwitz, W. Bai, E. B. Holmgren, P. Tobin, A. S. Guerrero, F. Kabbinavar, S. N. Holden, W. F. Novotny, G. D. Frantz, et al.
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer
J. Clin. Oncol., January 10, 2006; 24(2): 217 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
C. R. Pradeep, E. S. Sunila, and G. Kuttan
Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies
Integr Cancer Ther, December 1, 2005; 4(4): 315 - 321.
[Abstract] [PDF]

Home page
 BloodHome page
K. Kirito, N. Fox, N. Komatsu, and K. Kaushansky
Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1{alpha}
Blood, June 1, 2005; 105(11): 4258 - 4263.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Manenti, E. Riccardi, S. Marchini, E. Naumova, I. Floriani, A. Garofalo, R. Dossi, E. Marrazzo, D. Ribatti, E. Scanziani, et al.
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy
Mol. Cancer Ther., May 1, 2005; 4(5): 715 - 725.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Dalal, A. M. Berry, C. J. Cullinane, D. C. Mangham, R. Grimer, I. J. Lewis, C. Johnston, V. Laurence, and S. A. Burchill
Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family
Clin. Cancer Res., March 15, 2005; 11(6): 2364 - 2378.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Hicklin and L. M. Ellis
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
J. Clin. Oncol., February 10, 2005; 23(5): 1011 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-P. Gerber and N. Ferrara
Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies
Cancer Res., February 1, 2005; 65(3): 671 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
J.S. RUDGE, G. THURSTON, S. DAVIS, N. PAPADOPOULOS, N. GALE, S.J. WIEGAND, and G.D. YANCOPOULOS
VEGF Trap as a Novel Antiangiogenic Treatment Currently in Clinical Trials for Cancer and Eye Diseases, and VelociGene(R)- based Discovery of the Next Generation of Angiogenesis Targets
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 411 - 418.
[Abstract] [PDF]

Home page
 Endocr. Rev.Home page
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev., August 1, 2004; 25(4): 581 - 611.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. A. Hesser, X. H. Liang, G. Camenisch, S. Yang, D. A. Lewin, R. Scheller, N. Ferrara, and H.-P. Gerber
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells
Blood, July 1, 2004; 104(1): 149 - 158.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. S. Chand, X. Du, D. Ma, H. D. Inzunza, S. Kamei, D. Foster, S. Brodie, and W. Kisiel
The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice
Blood, February 1, 2004; 103(3): 1069 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Huang, S. Z. Soffer, E. S. Kim, K. W. McCrudden, J. Huang, T. New, C. A. Manley, W. Middlesworth, K. O'Toole, D. J. Yamashiro, et al.
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Mol. Cancer Res., January 1, 2004; 2(1): 36 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Bockhorn, Y. Tsuzuki, L. Xu, A. Frilling, C. E. Broelsch, and D. Fukumura
Differential Vascular and Transcriptional Responses to Anti-Vascular Endothelial Growth Factor Antibody in Orthotopic Human Pancreatic Cancer Xenografts
Clin. Cancer Res., September 15, 2003; 9(11): 4221 - 4226.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Huang, J. S. Frischer, A. Serur, A. Kadenhe, A. Yokoi, K. W. McCrudden, T. New, K. O'Toole, S. Zabski, J. S. Rudge, et al.
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
PNAS, June 24, 2003; 100(13): 7785 - 7790.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher, N. J. Meropol, W. F. Novotny, G. Lieberman, S. Griffing, and E. Bergsland
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., January 1, 2003; 21(1): 60 - 65.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
H. Y. Shin, M. L. Smith, K. J. Toy, P. M. Williams, R. Bizios, and M. E. Gerritsen
VEGF-C mediates cyclic pressure-induced endothelial cell proliferation
Physiol Genomics, December 3, 2002; 11(3): 245 - 251.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, E. Burova, et al.
VEGF-Trap: A VEGF blocker with potent antitumor effects
PNAS, August 20, 2002; 99(17): 11393 - 11398.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. D. LAIRD, J. G. CHRISTENSEN, G. LI, J. CARVER, K. SMITH, X. XIN, K. G. MOSS, S. G. LOUIE, D. B. MENDEL, and J. M. CHERRINGTON
SU6668 inhibits Flk-1/KDR and PDGFR{beta} in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice
FASEB J, May 1, 2002; 16(7): 681 - 690.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Zheng, S. Deshpande, S. Lee, N. Ferrara, and B. T. Rouse
Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis
J. Virol., October 15, 2001; 75(20): 9828 - 9835.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.